Chemotherapy Induced Anemia Market Outlook 2031
The global chemotherapy induced anemia market size was valued at USD 2.70 Billion in 2022 and is projected to reach USD 4.68 Billion by 2031, expanding at a CAGR of 6.3% during the forecast period, 2023-2031. The market growth is attributed to the increasing number of anemia cases among the geriatric population and the rise in the incidence of cancer.
Furthermore, several initiatives taken by various organizations to spread awareness among people regarding such diseases present a key aspect of the market. Anemia is a health condition when the total amount of red blood cells decreases in the blood or the red blood cells present in the body are dysfunctional.
Oxygen binds with red blood cells with the help of hemoglobin, which acts as an essential part. The different organs of the body do not get the required amount of oxygen when the number of red blood cells is low or abnormal. Common symptoms of anemia are shortness of breath, dizziness, fatigue, having a fast heartbeat, and skin pallor.
Anemia can be caused due to deficiency of iron or having low vitamin levels. When the normal tissues are invaded by malignant, it leads to blood loss. Deficiency of iron that is functional and disruption of erythropoiesis with bone marrow infiltration can result in chemotherapy induced anemia.
Crucial outcomes of chemotherapy cause chemotherapy induced anemia. When an individual is diagnosed with chemotherapy induced anemia, it is quite possible that it may cause a delay to the therapy and is also expected to result in dropping off the life quality and induces fatigue.
Chemotherapy Induced Anemia Market Trends, Drivers, Restraints, and Opportunities
- Side effects caused by the treatment of cancer and the rise in the incidence of anemia in cancer patients due to several causes are expected to fuel the market growth.
- Increasing chronic inflammatory conditions and invasion of bone marrow are some of the major factors anticipated to drive the market expansion in the coming years.
- Advancement & innovation along with improvement in pipeline products are other key factors estimated to boost the market growth during the forecast period.
- Risk associated with treatment and side effects caused due to drugs are key challenges that can restrain the growth of the market during the forecast period.
- Presence of favorable reimbursement policies is projected to create lucrative opportunities for the growth of the market in the coming years.
Scope of Chemotherapy Induced Anemia Market Report
The report on the global chemotherapy induced anemia market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Chemotherapy Induced Anemia Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
Ranges of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, and Life-threatening Anemia), Treatment Types (RBC Transfusions, Iron Supplementation, and Erythropoiesis Stimulating Agents), Drug Types (Epogen Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, Procrit Injection, and Others), and End-users (Ambulatory Surgical Centers, Hospitals, Multispecialty Clinics, Cancer Rehabilitation Centers, and Cancer Research Centers)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Pfizer Inc.; Panacea Biotec.; Therapure Biopharma Inc.; Panacea Biotec Limited; SBI Pharmaceuticals Co., Ltd.; 3SBio Inc.; Tolero Pharmaceuticals, Inc.; Vifor Pharma AG; and Dr. Reddy’s Laboratories Ltd.
Chemotherapy Induced Anemia Market Segment Insights
Ranges of Anemia Segment Analysis
Based on ranges of anemia, the global chemotherapy induced anemia market is divide into mild anemia, moderate anemia, severe anemia, and life-threatening anemia.
The severe anemia segment is projected to hold a key market share in the coming years owing to wide number of patients having this range group. Moreover, patients of this group are mostly recommended by medical professionals to undergo urgent chemotherapy technique to stop further spread of the disease.
Treatment Segment Analysis
On the basis of treatment types, the market is segregated into RBC transfusions, iron supplementation, and erythropoiesis stimulating agents. The RBC transfusions segment is a fast-growing domain and is anticipated to register a high CAGR during the forecast period owing to wide adoption of the treatment method as it is a first-line approach for the disease treatment.
Drug Types Segment Analysis
In terms of drug types, the global chemotherapy induced anemia market is categorized as epogen injection, androxy oral, aranesp injection, epoetin alfa injection, procrit injection, and others. The epogen injection segment is expected to grow substantially during the projected period owing to the high adoption and wide availability of the drugs.
End-users Segment Analysis
Based on end-users, the market is segmented into ambulatory surgical centers, hospitals, multispecialty clinics, cancer rehabilitation centers, and cancer research centers. The cancer research centers segment is anticipated to register a high CAGR during the forecast period owing to extensive research on the field and availability of advanced technology for chemotherapy techniques.
However, the hospitals segment is projected to account for a key market share in the coming years owing to easy accessibility of hospitals and presence of highly specialized doctors and medical staffs.
In terms of regions, the global chemotherapy induced anemia market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in Asia Pacific held a large share of the market in 2019, which was followed by North America and Europe.
The market growth in Asia Pacific is expected to constitute a large market share during the forecast period attributed to innovations in the field of chemotherapy induced anemia, an enormous amount of awareness among people regarding such diseases, advancement of technologies for healthcare infrastructure, and initiatives taken by various governments in the region.
On the other hand, the market of Middle East & Africa is expected to grow at an extensive rate during the targeted period owing to increasing insubstantial expenditure for healthcare and the increasing number of people diagnosed with anemia in cancer patients.
The global chemotherapy induced anemia market has been segmented on the basis of
Ranges of Anemia
- Mild Anemia
- Moderate Anemia
- Severe Anemia
- Life-threatening Anemia
- RBC Transfusions
- Iron Supplementation
- Erythropoiesis Stimulating Agents
- Epogen Injection
- Androxy Oral
- Aranesp Injection
- Epoetin Alfa Injection
- Procrit Injection
- Ambulatory Surgical Centers
- Multispecialty Clinics
- Cancer Rehabilitation Centers
- Cancer Research Centers
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Pfizer, Inc.
- Clovis Oncology
- Celgene Corp.
- Amgen, Inc.
- Novartis AG
- PharmaCyte Biotech
- F. Hoffmann-La Roche AG
- IncTeva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Eli Lilly and Co.
Key players competing in the global chemotherapy induced anemia market are Pfizer, Inc.; Clovis Oncology; Celgene Corp.; Amgen, Inc.; Novartis AG; PharmaCyte Biotech; F. Hoffmann-La Roche AG; IncTeva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Eli Lilly and Co.
Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.